{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:15:36Z","timestamp":1791087336657,"version":"4.1.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4,15]]},"DOI":"10.1097\/qai.0b013e31820b844e","type":"journal-article","created":{"date-parts":[[2011,1,15]],"date-time":"2011-01-15T01:10:49Z","timestamp":1295053849000},"page":"393-400","source":"Crossref","is-referenced-by-count":30,"title":["CD40L-Containing Virus-Like Particle as a Candidate HIV-1 Vaccine Targeting Dendritic Cells"],"prefix":"10.1097","volume":"56","author":[{"given":"David","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice H","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210131","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1172\/JCI34706","article-title":"The spread, treatment, and prevention of HIV-1: evolution of a global epidemic.","volume":"118","author":"Cohen","year":"2008","journal-title":"J Clin Invest"},{"key":"R2-3-20210131","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrmicro1819","article-title":"The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.","volume":"2","author":"Karlsson","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"R3-3-20210131","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0952-7915(98)80118-0","article-title":"Protective immunity induced by live attenuated simian immunodeficiency virus.","volume":"10","author":"Johnson","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"R4-3-20210131","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1128\/JVI.73.6.4952-4961.1999","article-title":"Highly attenuated vaccine strains of Simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation.","volume":"73","author":"Johnson","year":"1999","journal-title":"J Virol"},{"key":"R5-3-20210131","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1128\/JVI.74.4.2038-2045.2000","article-title":"Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef.","volume":"4","author":"Sawai","year":"2000","journal-title":"J Virol"},{"key":"R6-3-20210131","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1006\/viro.1998.9237","article-title":"Morphopoietic determinants of HIV-1 gag particles assembled in baculovirus-infected cells.","volume":"247","author":"Gay","year":"1998","journal-title":"Virology"},{"key":"R7-3-20210131","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymeth.2006.05.024","article-title":"Virus-like particles: designing an effective AIDS vaccine.","volume":"40","author":"Young","year":"2006","journal-title":"Methods"},{"key":"R8-3-20210131","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-3542(00)00136-4","article-title":"High efficient production of Pr55gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A.","volume":"49","author":"Buonaguro","year":"2001","journal-title":"Antiviral Res"},{"key":"R9-3-20210131","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1128\/JVI.64.6.2653-2659.1990","article-title":"Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system.","volume":"46","author":"Haffar","year":"1990","journal-title":"J Virol"},{"key":"R10-3-20210131","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF01309579","article-title":"Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.","volume":"127","author":"Wagner","year":"1992","journal-title":"Arch Virol"},{"key":"R11-3-20210131","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/088922200309322","article-title":"Production and characterization of simian-human immunodeficiency virus-like particles.","volume":"16","author":"Yao","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R12-3-20210131","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1128\/JVI.72.6.4667-4677.1998","article-title":"Particle size determinants in the human immunodeficiency virus type 1 Gag protein.","volume":"72","author":"Garnier","year":"1998","journal-title":"J Virol"},{"key":"R13-3-20210131","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0264-410X(99)00200-5","article-title":"Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies.","volume":"18","author":"Notka","year":"1999","journal-title":"Vaccine"},{"key":"R14-3-20210131","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.vaccine.2007.11.043","article-title":"Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6\/11\/16\/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines.","volume":"26","author":"Wheeler","year":"2008","journal-title":"Vaccine"},{"key":"R15-3-20210131","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/135965350701200409","article-title":"Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.","volume":"12","author":"Vietheer","year":"2007","journal-title":"Antivir Ther"},{"key":"R16-3-20210131","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1517\/14712598.7.7.997","article-title":"Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer.","volume":"7","author":"Ramqvist","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"R17-3-20210131","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000150482","article-title":"Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen.","volume":"39","author":"Schirmbeck","year":"1996","journal-title":"Intervirology"},{"key":"R18-3-20210131","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1016\/j.vaccine.2010.02.057","article-title":"Trivalent human papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types.","volume":"28","author":"Zhang","year":"2010","journal-title":"Vaccine"},{"key":"R19-3-20210131","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.yexmp.2009.01.009","article-title":"Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer.","volume":"86","author":"Palmer","year":"2009","journal-title":"Exp Mol Pathol"},{"key":"R20-3-20210131","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vaccine.2008.06.002","article-title":"An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.","volume":"26","author":"Schiller","year":"2008","journal-title":"Vaccine"},{"key":"R21-3-20210131","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1084\/jem.194.6.769","article-title":"Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo.","volume":"194","author":"Hawiger","year":"2001","journal-title":"J Exp Med"},{"key":"R22-3-20210131","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1084\/jem.20021598","article-title":"Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8 T cell tolerance.","volume":"196","author":"Bonifaz","year":"2002","journal-title":"J Exp Med"},{"key":"R23-3-20210131","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.4049\/jimmunol.167.11.6247","article-title":"Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8 T cells in vitro, whereas CD40 ligation is essential.","volume":"167","author":"Kelleher","year":"2001","journal-title":"J Immunol"},{"key":"R24-3-20210131","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jlb.63.4.418","article-title":"The role of CD40\/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells.","volume":"63","author":"Mackay","year":"1998","journal-title":"J Leukocyte Biol"},{"key":"R25-3-20210131","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/eji.1830260838","article-title":"Differential activation requirements of isotype-switched B cells.","volume":"26","author":"Ehrhardt","year":"1996","journal-title":"Eur J Immunol"},{"key":"R26-3-20210131","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1146\/annurev.iy.12.040194.004313","article-title":"The CD40 antigen and its ligand.","volume":"12","author":"Banchereau","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"R27-3-20210131","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1016\/j.vaccine.2009.07.033","article-title":"Optimal induction of HPV DNA vaccine-induced CD8 T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.","volume":"27","author":"Seo","year":"2009","journal-title":"Vaccine"},{"key":"R28-3-20210131","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jgm.1412","article-title":"CD40-expressing plasmid induces anti-CD40 antibody and enhances immune responses to DNA vaccination.","volume":"12","author":"Xu","year":"2010","journal-title":"J Gene Med"},{"key":"R29-3-20210131","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-3542(00)00136-4","article-title":"High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A.","volume":"49","author":"Buonaguro","year":"2001","journal-title":"Antiviral Res"},{"key":"R30-3-20210131","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1128\/JVI.66.7.4003-4012.1992","article-title":"Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.","volume":"66","author":"Rovinski","year":"1992","journal-title":"J Virol"},{"key":"R31-3-20210131","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JVI.02263-06","article-title":"Role of the transmembrane domain of Marburg virus surface protein GP in assembly of the viral envelope.","volume":"8","author":"Mittler","year":"2007","journal-title":"J Virol"},{"key":"R32-3-20210131","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1084\/jem.20051639","article-title":"Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses.","volume":"203","author":"Boscardin","year":"2006","journal-title":"J Exp Med"},{"key":"R33-3-20210131","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1016\/j.vaccine.2010.06.052","article-title":"Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development.","volume":"28","author":"Franco","year":"2010","journal-title":"Vaccine"},{"key":"R34-3-20210131","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1128\/JVI.01692-06","article-title":"Incorporation of glycosylphosphatidylinositol-anchored granulocyte-macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles.","volume":"81","author":"Skountzou","year":"2007","journal-title":"J Virol"},{"key":"R35-3-20210131","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1016\/j.vaccine.2010.03.079","article-title":"Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.","volume":"28","author":"Zhang","year":"2010","journal-title":"Vaccine"},{"key":"R36-3-20210131","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1128\/JVI.01870-08","article-title":"Incorporation of CD40 ligand into the envelope of pseudotyped single-cycle simian immunodeficiency viruses enhances immunogenicity.","volume":"83","author":"Lin","year":"2009","journal-title":"J Virol"},{"key":"R37-3-20210131","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/smim.1994.1035","article-title":"Structural characteristics of CD40 ligand that determine biological function.","volume":"5","author":"Fanslow","year":"1994","journal-title":"Semin Immunol"},{"key":"R38-3-20210131","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/eji.1830250639","article-title":"A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation.","volume":"25","author":"Graf","year":"1995","journal-title":"Eur J Immunol"},{"key":"R39-3-20210131","doi-asserted-by":"crossref","first-page":"10168","DOI":"10.1021\/bi9909905","article-title":"High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization.","volume":"38","author":"Pullen","year":"1999","journal-title":"Biochemistry"},{"key":"R40-3-20210131","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/nsb1295-1075","article-title":"A trimeric structural domain of the HIV-1 transmembrane glycoprotein.","volume":"2","author":"Lu","year":"1995","journal-title":"Nat Struct Biol"},{"key":"R41-3-20210131","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.4049\/jimmunol.0802597","article-title":"Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.","volume":"183","author":"Wyzgol","year":"2009","journal-title":"J Immunol"},{"key":"R42-3-20210131","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1128\/JVI.00542-07","article-title":"Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles.","volume":"81","author":"Wang","year":"2007","journal-title":"J Virol"},{"key":"R43-3-20210131","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/mt.sj.6300131","article-title":"Avian influenza virus hemagglutinin display on baculovirus envelope: cytoplasmic domain affects virus properties and vaccine potential.","volume":"15","author":"Yang","year":"2007","journal-title":"Mol Ther"},{"key":"R44-3-20210131","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.184.2.747","article-title":"Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via antigen-presenting cell activation.","volume":"184","author":"Cella","year":"1996","journal-title":"J Exp Med"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-201104150-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:49:55Z","timestamp":1786042195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201104150-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,15]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31820b844e","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,15]]}}}